The de novo purine synthesis pathway is an established therapeutic vulnerability in small cell lung cancer (SCLC) and other tumor types. However, crosstalk between de novo purine synthesis and purine salvage—a second purine synthesis pathway—and corresponding therapeutic implications remain poorly defined. In their study, Tabata and colleagues observed expression of hypoxanthine phosphoribosyltransferase 1 (HPRT1), a rate-limiting enzyme in the purine salvage pathway, in SCLC samples and cell lines using immunohistochemistry and Western blotting, respectively. By eliminating HPRT1 expression using CRISPR-Cas9 in SCLC cell lines and treating them with a pharmacologic de novo purine synthesis inhibitor, the authors showed that purine salvage abrogation increased SCLC cell sensitivity to de novo purine synthesis inhibition. Similar findings were recapitulated with HPRT1-deficient xenografts in a mouse model. Metabolomic and isotope tracing experiments demonstrated that HPRT1 depletion increased abundances of de novo purine synthesis pathway metabolic intermediates. In sum, this study implicates purine salvage...
Skip Nav Destination
Article navigation
1 January 2024
Highlights|
January 02 2024
Selected Articles from This Issue
Online ISSN: 1557-3125
Print ISSN: 1541-7786
©2024 American Association for Cancer Research
2024
American Association for Cancer Research
Mol Cancer Res (2024) 22 (1): 5.
- Views Icon Views
- Share Icon Share
-
Tools Icon
Tools
- Search Site
-
Article Versions Icon
Versions
- Version of Record January 2 2024
Citation
Selected Articles from This Issue. Mol Cancer Res 1 January 2024; 22 (1): 5. https://doi.org/10.1158/1541-7786.MCR-22-1-HI
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Pay-Per-View 24-Hour Access
$50.00
70
Views
Citing articles via
Advertisement